Community/Retail

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Officials with the FDA have approved pertuzumab (Perjeta, Roche) in combination with trastuzumab and chemotherapy as an adjuvant therapy for patients with early-stage human epidermal growth factor receptor 2 positive (HER2+) breast cancer who are at high risk of experiencing recurrence.

Officials with the FDA have finalized a rule that bans 24 active ingredients, including triclosan, from being marketed and sold in OTC health care antiseptic products.

FDA officials are now requiring a new patient medication guide, providing educational information that every patient will be asked to read before receiving a GBCA, and they are requiring manufacturers of GBCAs to conduct human and animal studies to further assess the safety of these contrast agents.

Pharmacists should be aware of what components they need to address to comply in order to prep themselves for USP standards.